Tuesday, October 13, 2026

Tattooed Chef Already 4% Up, Almost Two Hours Before The NASDAQ Open

ViaNews Editorial Team

February 8, 2023

Tattooed Chef Already 4% Up, Almost Two Hours Before The NASDAQ Open

(VIANEWS) - The NASDAQ opens in less than two hours and Tattooed Chef's pre-market value is already 4.96% up.

Tattooed Chef's last close was $1.41, 94.44% under its 52-week high of $25.35.

The last session, NASDAQ ended with Tattooed Chef (TTCF) dropping 6.62% to $1.41. NASDAQ rose 1.9% to $12,113.79, following the last session's upward trend on what was an all-around up trend exchanging session.

About Tattooed Chef

Tattooed Chef, Inc., a plant-based food company, produces and sells a portfolio of frozen foods. It supplies plant-based products to retailers in the United States. The company offers ready-to-cook bowls, zucchini spirals, riced cauliflower, acai and smoothie bowls, cauliflower crust pizza, and plant-based burgers. Its products are available in private label and Tattooed Chef brand name in the frozen food section of retail food stores. As of December 31, 2021, it operated approximately 14,000 retail outlets. Tattooed Chef, Inc. is headquartered in Paramount, California.

Earnings Per Share

As for profitability, Tattooed Chef has a trailing twelve months EPS of $-0.069.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -38.9%.

Moving Average

Tattooed Chef's worth is way below its 50-day moving average of $9.89 and way under its 200-day moving average of $14.80.

Revenue Growth

Year-on-year quarterly revenue growth grew by 30%, now sitting on 213.43M for the twelve trailing months.

Volume

Today's last reported volume for Tattooed Chef is 1228250 which is 29.12% below its average volume of 1551940.

More news about Tattooed Chef (TTCF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com